Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Accumulated Expenses (2016 - 2025)

Cytosorbents' Accumulated Expenses history spans 15 years, with the latest figure at $6.3 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $6.3 million for Q4 2025, up 4.43% from a year ago — trailing twelve months through Dec 2025 was $6.3 million (up 4.43% YoY), and the annual figure for FY2025 was $6.3 million, up 4.43%.
  • Accumulated Expenses for Q4 2025 was $6.3 million at Cytosorbents, down from $6.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.3 million in Q4 2021 to a low of $5556.0 in Q4 2022.
  • The 5-year median for Accumulated Expenses is $6.8 million (2023), against an average of $6.5 million.
  • The sharpest move saw Accumulated Expenses plummeted 99.95% in 2022, then surged 60088.62% in 2023.
  • Year by year, Accumulated Expenses stood at $10.3 million in 2021, then plummeted by 99.95% to $5556.0 in 2022, then surged by 60088.62% to $3.3 million in 2023, then soared by 80.38% to $6.0 million in 2024, then grew by 4.43% to $6.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $6.3 million, $6.6 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.